UK Drug Watchdog Backs Novo Nordisk's Wegovy for Heart Disease Prevention via NHS

The UK's NICE recommends Wegovy for heart health, marking a major shift in NHS coverage for GLP-1 drugs amid a global pricing debate involving the Trump administration.

By: AXL Media

Published: Apr 1, 2026, 4:11 AM EDT

Source: Reuters

The Expansion of Wegovy into Cardiovascular Care In a pivotal move for the pharmaceutical sector, the UK’s drug cost-effectiveness watchdog, NICE, has officially endorsed Novo Nordisk’s Wegovy for use in reducing serious cardiovascular risks. This recommendation marks the first time a GLP-1 receptor agonist has been formally supported for this specific clinical application in the United Kingdom. Under the new guidance, a 2.4-milligram dose of the medication will be integrated into the National Health Service (NHS) cardiovascular treatment pathways. This allows clinicians to prescribe the drug as a standard secondary prevention therapy for overweight or obese adults who have already experienced heart problems.

Clinical Evidence and Regulatory Evolution The decision by NICE was heavily influenced by robust clinical data from a study involving over 17,600 participants. The trial demonstrated that Wegovy could reduce the risk of major adverse cardiovascular events by 20 percent when compared to a placebo group. While Wegovy received initial UK regulatory approval for cardiovascular risk reduction in 2024, patient access was previously restricted to those capable of paying out-of-pocket costs. By securing NICE’s recommendation, Novo Nordisk has effectively moved Wegovy from a niche weight-loss product to a critical public health tool in a country where approximately one in four adults lives with obesity.

The Geopolitical and Pricing Conflict The rollout of these advanced therapies arrives during a period of intense friction between global pharmaceutical companies and European health systems. Rival drugmaker Eli Lilly has recently pressured the UK government to increase NHS drug prices and eliminate multi-billion-pound rebate schemes. This industry pushback is partly driven by the Trump administration’s efforts to force European nations to pay higher prices for medicines, intended to facilitate price reductions within the United States. Last year, Lilly increased the UK list price for its competing drug, Mounjaro, by as much as 170 percent, highlighting the volatile pricing environment for GLP-1 medications.

Strategic Rationale and Market Dynamics For Novo Nordisk, the NICE endorsement provides a significant strategic advantage in the "weight-loss war" against competitors like Eli Lilly. By establishing Wegovy as a cardiovascular necessity rather than just a li...